New Two-Pronged attack on deadly melanoma in the liver
NCT ID NCT07281924
Summary
This study is testing a new combination treatment for people with metastatic melanoma that has spread to the liver. It combines a liver-targeted chemotherapy (HEPZATO KIT™) with a two-drug immunotherapy (Opdualag™). The main goals are to see if this combination is safe and if it works better to shrink tumors than standard immunotherapy alone.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Hospital and Clinics
RECRUITINGMadison, Wisconsin, 53792, United States
Conditions
Explore the condition pages connected to this study.